The effect of sarcopenia on toxicity during chemotherapy in patients with pancreatic cancer
- Authors: Seryakov A.P.1, Klunichenko A.A.2, Seryakova A.A.3, Demidov S.M.4
-
Affiliations:
- Multidisciplinary medical holding «SM-Clinic»
- Treatment and Rehabilitation Center, Ministry of Health of the Russian Federation
- State Budgetary Institution of Healthcare of the city of Moscow «Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology»
- Ural State Medical University, Ministry of Health of the Russian Federation
- Issue: Vol 345, No 2 (2024)
- Pages: 49-53
- Section: Treatment and prophylactic issues
- URL: https://journals.eco-vector.com/0026-9050/article/view/627371
- DOI: https://doi.org/10.52424/00269050_2024_345_2_49
- ID: 627371
Cite item
Open Access
Access granted
Abstract
The influence of sarcopenia on the development of general and hematological toxicity during chemotherapy in patients with locally advanced and metastatic pancreatic cancer was studied. The study included 66 patients with pancreatic cancer (average age 59.3 years) undergoing chemotherapy treatment. Sarcopenia was examined on computed tomographs with a slice thickness of 1.5 mm. The results of the study suggest that sarcopenia in patients with locally advanced and metastatic pancreatic cancer may be a predictor of worse survival prognosis. Also, sarcopenia, which, in fact, is a predictor of increased toxicity of chemotherapy, including associated with an increased risk of anemia and thrombocytopenia, leukopenia, although no significant differences were found. This confirms that sarcopenia does not have a drastic effect on hematological toxicity. The above circumstances should be considered in the process of chemotherapeutic treatment of patients with pancreatic cancer, and if sarcopenia is detected and hematological toxicity develops, appropriate therapy should be carried out in a timely manner.
Keywords
Full Text
About the authors
A. P. Seryakov
Multidisciplinary medical holding «SM-Clinic»
Author for correspondence.
Email: professordemidov@mail.ru
профессор, полковник медицинской службы запаса
Russian Federation, MoscowA. A. Klunichenko
Treatment and Rehabilitation Center, Ministry of Health of the Russian Federation
Email: professordemidov@mail.ru
Russian Federation, Moscow
A. A. Seryakova
State Budgetary Institution of Healthcare of the city of Moscow «Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology»
Email: professordemidov@mail.ru
Russian Federation, Moscow
S. M. Demidov
Ural State Medical University, Ministry of Health of the Russian Federation
Email: professordemidov@mail.ru
профессор, капитан медицинской службы запаса
Russian Federation, YekaterinburgReferences
- Клуниченко А.А., Серяков А.П., Прокофьева А.А., Демидов С.М. Распространенность саркопенического ожирения у пациентов с раком поджелудочной железы // Тер. архив. – 2022. – Т. 94, № 2. – Приложение. – 304 с.
- Basile D., Parnofiello A., Vitale M.G. et al. The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients. // J. Cachexia Sarcopenia Muscle. – 2019. – Vol. 10, N 2. – P. 368–377.
- Carrara G., Pecorelli N., De Cobelli F. et al. Preoperative sarcopenia determinants in pancreatic cancer patients. // Clin. Nutr. – 2017. – Vol. 36, N 6. – P. 1649–1653.
- Choi M.H., Yoon S.B., Lee K. et al. Preoperative sarcopenia and post-operative accelerated muscle loss negatively impact survival after resection of pancreatic cancer // J. Cachexia Sarcopenia Muscle. – 2018. – Vol. 9, N 2. – P. 326–334.
- Cruz-Jentoft A.J., Bahat G., Bauer J. et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis // Age Ageing. – 2019. – Vol. 48, N 1. – P. 16–31.
- Daly L.E., Nн Bhuachalla Й.B., Power D.G. et al. Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer // J. Cachexia Sarcopenia Muscle. – 2018. – Vol. 9, N 2. – P. 315–325.
- Huang L., Jansen L., Balavarca Y. et al. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. // Gut. – 2019. – Vol. 68, N 1. – P. 130–139.
- Kays J.K., Shahda S., Stanley M. et al. Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer // J. Cachexia Sarcopenia Muscle. – 2018. – Vol. 9, N 4. – P. 673–684.
- Klunichenko A.A., Seryakov A.P., Seryakova A.A., Demidov S.M. Sarcopenia as a Prognostic Factor of Hepatotoxicity and Lower Survival Rate in Chemotherapy of Pancreatic Cancer // Rus. J. of Gastroenterol., Hepatol., Coloproctology. – 2020. – Vol. 30, N 3. – P. 49–54.
- Kurita Y., Kobayashi N., Tokuhisa M. et al. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy // Pancreatology. – 2019. – Vol. 19, N 1. – P. 127–135.
- Neoptolemos J.P., Palmer D.H., Ghaneh P. et al. European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial // Lancet. – 2017. – Vol. 389, N 10073. – P. 1011–1024.
- Pamukjian F., Boule T., Levi V. et al. Prevalence and prognostic value of pre-therapeutic sarcopenia in cancer patients: a systematic review // Clin. Nutr. – 2018. – Vol. 37, N 4. – P. 1101–1113.
- Prado C.M., Lieffers J.R., McCargar L.J. et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study // Lancet Oncol. – 2008. – Vol. 9, N 7. – P. 629–35.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).